Sunakawa, Yu
Takahashi, Keishiro
Kawaguchi, Osamu
Yamamoto, Nobuyuki
Article History
Received: 1 April 2022
Accepted: 1 June 2022
First Online: 30 June 2022
Declarations
:
: The protocol was approved by independent ethics committees at both participating centers and the study was conducted in accordance with the ethical principles laid out in the Declaration of Helsinki.
: All patients provided written informed consent prior to the initiation of any study-related procedures.
: The funding source (Sanofi) was involved in data collection, data analysis, data interpretation, and drafting the manuscript. Yu Sunakawa reports research grants (in the past 36 months) from Chugai Pharma, Taiho Pharma, Takeda, and Otsuka Pharma; and honoraria/lecture fees/speakers’ fees (in the past 36 months) from Eli Lilly Japan, Bristol-Myers Squibb, Chugai Pharma, Ono Pharma, Daiichi-Sankyo, Sysmex, Taiho Pharma, Merck Biopharma, Takeda, Bayer, and Guardant Japan. Keishiro Takahashi and Osamu Kawaguchi are employees of Sanofi and may hold shares and/or stock options in the company. Nobuyuki Yamamoto reports honoraria/lecture fees/speakers’ fees (in the past 36 months) from MSD, Chugai Pharma, Ono Pharma, AstraZeneca, Takeda Pharma, Eli Lilly Japan, Novartis, Pfizer, Janssen, Taiho Pharma, Daiichi-Sankyo, Amgen, Eisai, Toppan Printing, and Boehringer Ingelheim.